Data / Form D filings / NEKTAR THERAPEUTICS
NEKTAR THERAPEUTICS: Form D filings
NEKTAR THERAPEUTICS, a pharmaceuticals company in San Francisco, CA, filed 2 Form D notices with the SEC between 2018 and 2024. The latest, on March 19, 2024, reports $30 million sold of a $30 million offering to 1 investor.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 455 Mission Bay Boulevard South, San Francisco, CA, 94158
- Phone
- (415) 482-5300
- Industry
- Pharmaceuticals
- Entity type
- Corporation
- Incorporated in
- Delaware
- Revenue range
- $25,000,001 - $100,000,000
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 906709
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Mar 19, 2024 | New notice | $30,000,000 | $30,000,000 | 1 | Mar 4, 2024 | sec.gov | |
| Apr 3, 2018 | New notice | $849,999,960 | $849,999,960 | 1 | Apr 3, 2018 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Roy A Whitfield | Director | |
| Mark A Wilson | Executive Officer | |
| Sandra W Gardiner | Executive Officer | |
| Jeffrey R Ajer | Director | |
| Howard W Robin | Executive Officer, Director | |
| Diana M Brainard | Director | |
| Robert B Chess | Director | |
| R. Scott M Greer | Director | |
| Jonathan A Zalevsky | Executive Officer |
Other pharmaceuticals companies in California that filed recently
- Anvion Bio, Inc. $100,000 · Oct 7, 2026
- Aqur Biosciences, Inc. $1.5 million · Sep 18, 2026
- BTB Therapeutics, Inc. $8.9 million · Aug 12, 2026
Every Form D from the week of Mar 18, 2024 · All recent filings in California · All recent Pharmaceuticals filings
Read from SEC EDGAR. Amount sold is what NEKTAR THERAPEUTICS reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.